Craft

Vir Biotechnology

Stock Price

$7.6

2024-10-29

Market Capitalization

$1 B

2024-10-29

Revenue

$86.2 M

FY, 2023

Vir Biotechnology Summary

Company Summary

Overview
Vir Biotechnology is a company focused on developing therapies to prevent and treat infectious diseases. It designs and develops monoclonal antibodies, vaccines, and antiviral therapies targeting pathogens such as influenza, hepatitis B, and SARS-CoV-2. The company serves the healthcare and biopharmaceutical industries.
Type
Public
Status
Active
Founded
2016
HQ
San Francisco, CA, US | view all locations
Website
https://www.vir.bio/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • George Scangos

    George Scangos, President, Chief Executive Officer and Director

    • Aine Hanly

      Aine Hanly, Chief Technology Officer

      • Howard Horn

        Howard Horn, CFO

        • Antonio Lanzavecchia

          Antonio Lanzavecchia, Senior Vice President and Senior Research Fellow

          Operating MetricsView all

          Scientific Collaborations

          5

          Oct, 2019

          Drugs in Development

          5

          Oct, 2019

          Technology Platforms

          4

          Oct, 2019

          LocationsView all

          2 locations detected

          • San Francisco, CA HQ

            United States

            1800 Owens St #900

          • Bellinzona, TI

            Switzerland

            Via dei Gaggini 3

          Vir Biotechnology Financials

          Summary Financials

          Revenue (Q3, 2024)
          $2.4M
          Gross profit (Q3, 2024)
          $2.3M
          Net income (Q3, 2024)
          ($213.7M)
          Cash (Q3, 2024)
          $168.4M
          EBIT (Q3, 2024)
          ($231.3M)
          Enterprise value
          $984.3M

          Footer menu